<div class="infobox infobox-company">
<div class="infobox-header">Araclon Biotech S.L.</div>
<div class="infobox-row"><strong>Headquarters:</strong> Zaragoza, Spain</div>
<div class="infobox-row"><strong>Founded:</strong> 2008</div>
<div class="infobox-row"><strong>Parent Company:</strong> Grifols</div>
<div class="infobox-row"><strong>Private:</strong> Wholly-owned subsidiary</div>
<div class="infobox-row"><strong>Status:</strong> Active</div>
</div>
<div class="infobox infobox-company">
<div class="infobox-header">Araclon Biotech S.L.</div>
<div class="infobox-row"><strong>Headquarters:</strong> Zaragoza, Spain</div>
<div class="infobox-row"><strong>Founded:</strong> 2008</div>
<div class="infobox-row"><strong>Parent Company:</strong> Grifols</div>
<div class="infobox-row"><strong>Private:</strong> Wholly-owned subsidiary</div>
<div class="infobox-row"><strong>Status:</strong> Active</div>
</div>
Araclon Biotech is a Spanish biotechnology company focused on the development of therapies and diagnostic tools for [Alzheimer's disease](/diseases/alzheimers-disease). Founded in 2008 and headquartered in Zaragoza, Spain, the company is a wholly-owned subsidiary of Grifols, a leading global healthcare company known for its plasma-derived products["@araclon"].
Araclon takes a distinctive approach to Alzheimer's disease therapy by focusing on the [amyloid-beta](/proteins/amyloid-beta) 40 (Abeta40) isoform rather than the more commonly targeted Abeta42. This differentiated strategy may offer advantages in safety and efficacy, as Abeta40 is the most abundant isoform in the brain and may play a distinct pathological role["@alzheimers2020"].
Araclon operates as a fully integrated subsidiary of Grifols, benefiting from:
Araclon's mission is to develop disease-modifying therapies for Alzheimer's disease through:
ABvac40 is Araclon's lead clinical candidate, an active immunotherapy vaccine targeting amyloid-beta 40[@abvac].
| Attribute | Details |
|-----------|---------|
| Type | Active immunotherapy (vaccine) |
| Target | Amyloid-beta 40 (Aβ40) |
| Mechanism | Generates anti-Aβ40 antibodies |
| Indication | Alzheimer's Disease (early/mild) |
| Route | Subcutaneous injection |
| Development Phase | Phase 2 |
| Status | Active clinical development |
Why Aβ40?
Most Alzheimer's immunotherapy programs target Aβ42, the less abundant isoform. Araclon's focus on Aβ40 represents a differentiated approach:
Clinical Development:
AR-1801 is a monoclonal antibody targeting amyloid-beta, in preclinical development[@program].
| Attribute | Details |
|-----------|---------|
| Type | Monoclonal antibody (passive immunotherapy) |
| Target | Amyloid-beta |
| Indication | Alzheimer's Disease |
| Development Phase | Preclinical |
| Status | Active research |
Araclon has developed CSF (cerebrospinal fluid)-based biomarker assays for Alzheimer's disease diagnosis[@araclona].
| Product | Target | Application |
|---------|--------|-------------|
| Aβ40 ELISA | Amyloid-beta 40 | AD diagnosis |
| Aβ42 ELISA | Amyloid-beta 42 | AD diagnosis |
| Total tau | [Tau protein](/proteins/tau) | Neurodegeneration marker |
| Phospho-tau | Phosphorylated tau | AD diagnosis |
These diagnostic tools support patient selection and monitoring in clinical trials.
Araclon develops both active and passive immunization strategies:
Active Immunization (Vaccines):
Araclon's focus on Aβ40 offers several potential advantages:
The Phase 1 trial demonstrated[@abvaca]:
The ongoing Phase 2 trial is evaluating:
Alzheimer's disease represents one of the largest unmet medical needs:
| Company | Drug | Target | Stage |
|---------|------|--------|-------|
| Biogen/Eisai | Leqembi (Lecanemab) | Aβ protofibrils | Approved |
| Eli Lilly | Donanemab | Aβ plaque | Approved |
| Roche | Gantenerumab | Aβ plaque | Phase 3 |
| Araclon | ABvac40 | Aβ40 | Phase 2 |
| Prothena | PRX012 | Aβ | Phase 1 |
Araclon is funded through its parent company Grifols:
The following diagram shows the key molecular relationships involving Araclon Biotech S.L. discovered through SciDEX knowledge graph analysis: